EMILY WALLACE: Open Payments
NPI 1326680331 · BELDING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$692 in 33 payments from 13 companies in 2025. Trend: 2023 $1,014 · 2024 $820 · 2025 $692
Food & beverage: $692
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $146 |
| Novo Nordisk Inc | 5 | $109 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| ABBVIE INC. | 4 | $78 |
| Supernus Pharmaceuticals, Inc. | 3 | $63 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
Products named: REXULTI, FARXIGA, AIRSUPRA, Qelbree, Ozempic, CAPLYTA, VRAYLAR, Wegovy.
Industry payments across MI — which companies pay providers there.
